TLSI TriSalus Life Sciences, Inc.
Nasdaq · SEC CIK 1826667 · EDGAR
- Bought, last 12 months
- $3.61M 12 purchases by 6 insiders
- Sold, last 12 months
- $135.8K 6 sales by 5 insiders
- Filings on record
- 119 since 2023-06-14, latest 2026-07-06 16:01
BoughtSold
Most active insiders, 12 months
| Insider | Title | Bought | Sold |
|---|---|---|---|
| Stansky Michael P | Dir | $3.01M | — |
| Szela Mary T | CEO, Pres, Dir | $227.8K | $79.4K |
| Wahlstrom Mats | Dir | $151.8K | — |
| Valle William | Dir | $125.0K | — |
| Gordon Gary B. | Dir | $64.6K | — |
| Patience David | CFO | $32.2K | — |
| Marshak Richard | Chief Commercial Off | — | $15.7K |
| Stevens Jennifer | Chief Regulatory Off | — | $14.5K |
| Devlin Jodi | Chief of Clinical Ops | — | $13.2K |
| Cox Bryan F. | Chief of Research | — | $13.1K |
Transactions 89
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-07-06 16:01 | 2026-07-01 | TLSI | Patience David | CFO | F - Tax | $4.46 | -14.7K | 261.1K | -5% | -$65.3K | |
| 2026-07-01 16:04 | 2026-06-30 | TLSI | Szela Mary T | CEO, Pres, Dir | A - Grant | $3.87 | +3,990 | 1.08M | +0.4% | +$15.4K | |
| 2026-07-01 16:02 | 2026-06-30 | TLSI | Marshak Richard | Chief Commercial Off | A - Grant | $3.87 | +561 | 128.3K | +0.4% | +$2,171 | |
| D | 2026-06-29 16:33 | 2026-06-29 | TLSI | Marshall Richard Henry | Chief Medical Off | A - Grant | $0.00 | +60.0K | 90.0K | +200% | $0 |
| 2026-05-19 16:08 | 2026-05-15 | TLSI | Marshak Richard | Chief Commercial Off | S - Sale | $2.67 | -543 | 125.1K | -0.4% | -$1,450 | |
| 2026-05-18 16:42 | 2026-05-15 | TLSI | Wahlstrom Mats | Dir | P - Purchase | $2.53 | +60.0K | 147.6K | +69% | +$151.8K | |
| 2026-05-18 16:42 | 2026-05-15 | TLSI | Stansky Michael P | Dir | P - Purchase | $2.50 | +410.0K | 1.24M | +49% | +$1.02M | |
| I | 2026-05-18 16:42 | 2026-05-15 | TLSI | Stansky Michael P | Dir | P - Purchase | $2.50 | +200.0K | 399.7K | +100% | +$500.0K |
| 2026-05-18 16:42 | 2026-05-15 | TLSI | Szela Mary T | CEO, Pres, Dir | P - Purchase | $2.59 | +39.7K | 1.07M | +4% | +$102.8K | |
| 2026-05-18 16:42 | 2026-05-15 | TLSI | Patience David | CFO | P - Purchase | $2.43 | +7,100 | 275.8K | +3% | +$17.3K | |
| 2026-05-18 16:42 | 2026-05-15 | TLSI | Gordon Gary B. | Dir | P - Purchase | $2.46 | +10.0K | 72.5K | +16% | +$24.6K | |
| D | 2026-05-15 16:39 | 2026-05-14 | TLSI | HICKS KERRY R | Dir | A - Grant | $0.00 | +28.2K | 542.8K | +5% | $0 |
| DM | 2026-05-15 16:39 | 2026-05-14 | TLSI | Wahlstrom Mats | Dir | A - Grant | $0.00 | +71.8K | 87.6K | +457% | $0 |
| DM | 2026-05-15 16:39 | 2026-05-14 | TLSI | Gordon Gary B. | Dir | A - Grant | $0.00 | +52.8K | 62.5K | +541% | $0 |
| DM | 2026-05-15 16:39 | 2026-05-14 | TLSI | MATLIN DAVID J | Dir | A - Grant | $0.00 | +51.3K | 1.32M | +4% | $0 |
| DM | 2026-05-15 16:39 | 2026-05-14 | TLSI | Valle William | Dir | A - Grant | $0.00 | +52.8K | 83.2K | +173% | $0 |
| DM | 2026-05-15 16:39 | 2026-05-14 | TLSI | Stansky Michael P | Dir | A - Grant | $0.00 | +43.6K | 830.7K | +6% | $0 |
| D | 2026-04-20 16:36 | 2025-07-31 | TLSI | Frankenius Equity AB | 10% | C - Cnv Deriv | $0.00 | +759.0K | 6.99M | +12% | $0 |
| D | 2026-04-01 16:09 | 2025-07-31 | TLSI | MATLIN DAVID J | Dir | C - Cnv Deriv | $0.00 | +330.0K | 1.27M | +35% | $0 |
| M | 2026-03-20 | 2026-03-11+ | TLSI | Cox Bryan F. | Chief of Research | S - Sale | $4.11 | -3,184 | 163.4K | -2% | -$13.1K |
| M | 2026-03-20 | 2026-03-11+ | TLSI | Stevens Jennifer | Chief Regulatory Off | S - Sale | $4.11 | -3,530 | 124.1K | -3% | -$14.5K |
| M | 2026-03-20 | 2026-03-11+ | TLSI | Devlin Jodi | Chief of Clinical Ops | S - Sale | $4.11 | -3,207 | 97.4K | -3% | -$13.2K |
| M | 2026-03-20 | 2026-03-11+ | TLSI | Marshak Richard | Chief Commercial Off | S - Sale | $4.11 | -3,457 | 110.8K | -3% | -$14.2K |
| M | 2026-03-20 | 2026-03-11+ | TLSI | Szela Mary T | CEO, Pres, Dir | S - Sale | $3.91 | -20.3K | 768.9K | -3% | -$79.4K |
| 2026-02-23 | 2026-02-23 | TLSI | Gordon Gary B. | Dir | P - Purchase | $4.10 | +9,756 | 9,756 | New | +$40.0K | |
| 2026-02-23 | 2026-02-23 | TLSI | Szela Mary T | CEO, Pres, Dir | P - Purchase | $4.10 | +30.5K | 773.3K | +4% | +$125.0K | |
| 2026-02-23 | 2026-02-23 | TLSI | Valle William | Dir | P - Purchase | $4.10 | +30.5K | 30.5K | New | +$125.0K | |
| 2026-02-23 | 2026-02-23 | TLSI | Stansky Michael P | Dir | P - Purchase | $4.10 | +243.9K | 787.1K | +45% | +$1000.0K | |
| I | 2026-02-23 | 2026-02-23 | TLSI | Stansky Michael P | Dir | P - Purchase | $4.10 | +117.2K | 199.7K | +142% | +$480.5K |
| 2026-02-23 | 2026-02-23 | TLSI | Patience David | CFO | P - Purchase | $4.10 | +3,657 | 268.7K | +1% | +$15.0K | |
| D | 2025-11-25 | 2025-11-24 | TLSI | Marshak Richard | Chief Commercial Off | A - Grant | $0.00 | +60.0K | 113.9K | +111% | $0 |
| D | 2025-11-25 | 2025-11-24 | TLSI | Stevens Jennifer | Chief Regulatory Off | A - Grant | $0.00 | +50.0K | 127.6K | +64% | $0 |
| DM | 2025-11-25 | 2024-02-13+ | TLSI | Szela Mary T | CEO, Pres, Dir | A - Grant | $0.00 | +550.0K | 317.8K | New | $0 |
| D | 2025-11-25 | 2025-11-24 | TLSI | Patience David | CFO | A - Grant | $0.00 | +65.0K | 265.0K | +32% | $0 |
| D | 2025-11-25 | 2025-11-24 | TLSI | Devlin Jodi | Chief of Clinical Ops | A - Grant | $0.00 | +50.0K | 100.6K | +99% | $0 |
| D | 2025-11-25 | 2025-11-24 | TLSI | Cox Bryan F. | Chief of Research | A - Grant | $0.00 | +40.0K | 166.6K | +32% | $0 |
| D | 2025-08-15 | 2025-08-14 | TLSI | Patience David | CFO | A - Grant | $0.00 | +200.0K | 200.0K | New | $0 |
| 2025-05-21 | 2025-05-19 | TLSI | Cox Bryan F. | Chief of Research | A - Grant | $5.18 | +15.7K | 124.2K | +14% | +$81.4K | |
| 2025-05-21 | 2025-05-19 | TLSI | Cox Bryan F. | Chief of Research | S - Sale | $5.18 | -4,764 | 119.4K | -4% | -$24.7K | |
| 2025-05-21 | 2025-05-19 | TLSI | Young James Emmett | CFO | A - Grant | $5.18 | +13.2K | 49.7K | +36% | +$68.2K | |
| 2025-05-21 | 2025-05-19 | TLSI | Marshak Richard | Chief Commercial Off | S - Sale | $5.18 | -6,597 | 69.1K | -9% | -$34.2K | |
| 2025-05-21 | 2025-05-19 | TLSI | Marshak Richard | Chief Commercial Off | A - Grant | $5.18 | +21.4K | 75.7K | +39% | +$111.0K | |
| 2025-05-21 | 2025-05-19 | TLSI | Stevens Jennifer | Chief Regulatory Off | A - Grant | $5.18 | +28.5K | 86.3K | +49% | +$147.4K | |
| 2025-05-21 | 2025-05-19 | TLSI | Stevens Jennifer | Chief Regulatory Off | S - Sale | $5.18 | -8,704 | 77.6K | -10% | -$45.1K | |
| 2025-05-21 | 2025-05-19 | TLSI | Devlin Jodi | Chief of Clinical Ops | A - Grant | $5.18 | +24.1K | 57.5K | +72% | +$125.0K | |
| 2025-05-21 | 2025-05-19 | TLSI | Devlin Jodi | Chief of Clinical Ops | S - Sale | $5.18 | -4,764 | 52.8K | -8% | -$24.7K | |
| 2025-05-21 | 2025-05-19 | TLSI | Murphy Sean | Dir | A - Grant | $5.18 | +44.9K | 124.0K | +57% | +$232.5K | |
| 2025-02-19 | 2025-02-18 | TLSI | Stevens Jennifer | Chief REGULATORY Off | A - Grant | $0.00 | +14.5K | 57.9K | +33% | $0 | |
| 2025-02-19 | 2025-02-18 | TLSI | Murphy Sean | Chief Manuf, Strategy, Bus Dev, Dir | A - Grant | $0.00 | +15.8K | 79.1K | +25% | $0 | |
| 2025-02-19 | 2025-02-18 | TLSI | Marshak Richard | Chief Commercial Off | A - Grant | $0.00 | +7,644 | 54.3K | +16% | $0 | |
| 2025-02-19 | 2025-02-18 | TLSI | Cox Bryan F. | CHIEF OF RESEARCH | A - Grant | $0.00 | +11.4K | 108.5K | +12% | $0 | |
| 2025-02-19 | 2025-02-18 | TLSI | Devlin Jodi | Chief of Clinical Ops | A - Grant | $0.00 | +5,272 | 33.4K | +19% | $0 | |
| 2025-02-19 | 2025-02-18 | TLSI | Young James Emmett | CFO | A - Grant | $0.00 | +14.8K | 36.5K | +68% | $0 | |
| 2025-02-19 | 2025-02-18 | TLSI | Szela Mary T | CEO AND Pres, Dir | A - Grant | $0.00 | +21.1K | 465.3K | +5% | $0 | |
| I | 2025-02-06 | 2025-02-05 | TLSI | Young James Emmett | CFO | P - Purchase | $5.65 | +6,000 | 30.0K | +25% | +$33.9K |
| M | 2025-01-31 | 2025-01-29+ | TLSI | Szela Mary T | CEO AND Pres, Dir | P - Purchase | $5.15 | +10.0K | 439.2K | +2% | +$51.8K |
| D | 2025-01-29 | 2025-01-27 | TLSI | Stevens Jennifer | Chief REGULATORY Off | A - Grant | $0.00 | +10.6K | 43.4K | +32% | $0 |
| DM | 2025-01-29 | 2025-01-27+ | TLSI | Szela Mary T | CEO AND Pres, Dir | P - Purchase | $5.27 | +9,542 | 429.5K | +2% | +$50.3K |
| D | 2025-01-29 | 2025-01-27 | TLSI | Szela Mary T | CEO AND Pres, Dir | A - Grant | $0.00 | +40.0K | 424.7K | +10% | $0 |
| D | 2025-01-29 | 2025-01-27 | TLSI | Marshak Richard | Chief Commercial Off | A - Grant | $0.00 | +12.5K | 46.6K | +37% | $0 |
| D | 2025-01-29 | 2025-01-27 | TLSI | Devlin Jodi | Chief of COMMERC. Ops | A - Grant | $0.00 | +10.6K | 28.1K | +61% | $0 |
| D | 2025-01-29 | 2025-01-27 | TLSI | Cox Bryan F. | CHIEF OF RESEARCH | A - Grant | $0.00 | +10.6K | 97.0K | +12% | $0 |
| DMI | 2025-01-29 | 2025-01-27+ | TLSI | Murphy Sean | Chief Manuf, Strategy, Bus Dev, Dir | P - Purchase | $5.24 | +30.0K | 197.7K | +18% | +$157.2K |
| D | 2025-01-29 | 2025-01-27 | TLSI | Murphy Sean | Chief Manuf, Strategy, Bus Dev, Dir | A - Grant | $0.00 | +12.5K | 63.3K | +25% | $0 |
| DI | 2025-01-29 | 2025-01-27 | TLSI | Young James Emmett | CFO | P - Purchase | $5.40 | +24.0K | 24.0K | New | +$129.6K |
| D | 2025-01-29 | 2025-01-27 | TLSI | Young James Emmett | CFO | A - Grant | $0.00 | +12.5K | 21.7K | +135% | $0 |
| 2025-01-06 | 2025-01-02 | TLSI | Hyveled Liselotte | Dir | A - Grant | $0.00 | +10.0K | 10.0K | New | $0 | |
| 2025-01-06 | 2025-01-02 | TLSI | MATLIN DAVID J | Dir | A - Grant | $0.00 | +10.0K | 941.9K | +1% | $0 | |
| 2024-12-19 | 2024-10-05 | TLSI | Cox Bryan F. | CHIEF SCIENTIFIC, MANUFACT | S - Sale | $4.44 | -314 | 86.4K | -0.4% | -$1,394 | |
| 2024-12-19 | 2024-12-17 | TLSI | Wahlstrom Mats | Dir, 10% | A - Grant | $3.97 | +25.2K | 40.9K | +160% | +$100.0K | |
| 2024-12-19 | 2024-12-17 | TLSI | Frankenius Equity AB | 10% | P - Purchase | $3.97 | +63.0K | 6.23M | +1% | +$250.0K | |
| 2024-12-12 | 2024-12-10 | TLSI | Desai Arjun JJ | Dir | S - Sale | $3.69 | -30.0K | 247.1K | -11% | -$110.7K | |
| 2024-11-25 | 2024-11-22 | TLSI | Wahlstrom Mats | Dir, 10% | P - Purchase | $4.55 | +5,000 | 15.7K | +47% | +$22.8K | |
| M | 2024-11-22 | 2024-11-20+ | TLSI | Wahlstrom Mats | Dir, 10% | P - Purchase | $4.39 | +10.7K | 2,040 | New | +$47.1K |
| D | 2024-11-15 | 2024-11-14 | TLSI | Marshak Richard | SR.VP, CORP. DEV, STRATEGY | A - Grant | $0.00 | +6,875 | 34.1K | +25% | $0 |
| M | 2024-09-13 | 2024-09-12+ | TLSI | Szela Mary T | CEO AND Pres, Dir | P - Purchase | $5.09 | +14.8K | 384.7K | +4% | +$75.4K |
| 2024-09-12 | 2024-09-10 | TLSI | Szela Mary T | CEO AND Pres, Dir | P - Purchase | $4.97 | +5,000 | 369.9K | +1% | +$24.9K | |
| I | 2024-09-10 | 2024-08-28 | TLSI | Martin George Kelly | Dir | S - Sale | $5.50 | -9 | 247.2K | -0.0% | -$49.50 |
| D | 2024-07-02 | 2024-07-01 | TLSI | Desai Arjun JJ | Dir | A - Grant | — | +74.0K | 277.1K | +36% | — |
| D | 2024-02-14 | 2024-02-12 | TLSI | Marshak Richard | SR.VP, CORP. DEV, STRATEGY | A - Grant | $0.00 | +14.8K | 27.3K | +118% | $0 |
| D | 2024-02-14 | 2024-02-12 | TLSI | Stevens Jennifer | Chief REGULATORY Off | A - Grant | $0.00 | +14.8K | 32.8K | +82% | $0 |
| D | 2024-02-14 | 2024-02-12 | TLSI | Devlin Jodi | Pres, COMMERC. Ops | A - Grant | $0.00 | +17.5K | 17.5K | New | $0 |
| D | 2024-02-14 | 2024-02-12 | TLSI | Murphy Sean | CFO, Dir | A - Grant | $0.00 | +34.1K | 50.8K | +205% | $0 |
| D | 2024-02-14 | 2024-02-13 | TLSI | Szela Mary T | CEO AND Pres, Dir | A - Grant | $0.00 | +84.9K | 364.9K | +30% | $0 |
| D | 2024-02-14 | 2024-02-12 | TLSI | Cox Bryan F. | CHIEF SCIENTIFIC, MANUFACT | A - Grant | $0.00 | +14.8K | 86.7K | +21% | $0 |
| D | 2024-02-14 | 2024-02-12 | TLSI | Katz Steven C | Chief MEDICAL Off | A - Grant | $0.00 | +34.1K | 68.6K | +99% | $0 |
| D | 2023-08-14 | 2023-08-10 | TLSI | MATLIN DAVID J | Dir | J - Other | — | +931.9K | 931.9K | New | — |
| D | 2023-06-27 | 2023-06-26 | TLSI | Dewey Christopher C | 10% | C - Cnv Deriv | — | +6.25M | 6.25M | New | — |
| MI | 2023-06-14 | 2023-06-12 | TLSI | Snyderman David J. | 10% | J - Other | $10.49 | -445.8K | 1 | -100% | -$4.68M |
Purchase Sale Sale after option exercise All abbreviations